Storia in 2 fonti

PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction

The bankrupt gene editing biotech Sangamo is set to sell chunks of its business to PTC Therapeutics and Eli Lilly for up to $264 million following an auction procedure.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo16 h fa

PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction

The bankrupt gene editing biotech Sangamo is set to sell chunks of its business to PTC Therapeutics and Eli Lilly for up to $264 million following an auction procedure.

originale

biopharmadive.com1 g fa

PTC takes a chance on Sangamo’s Fabry disease gene therapy

PTC acquired gene therapy ST-920 for Fabry from bankrupt Sangamo for $111M upfront plus $100M in FDA milestones, targeting 2027 launch. Gene therapies remain viable; the $2B+ market and ST-920's edge justify PTC's rare-disease bet with infrastructure synergies.

Leggi questa versione →

Timeline cronologica

giovedì 13 agosto 2026·biopharmadive.com
PTC takes a chance on Sangamo’s Fabry disease gene therapy
Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.
giovedì 13 agosto 2026·endpoints.news
PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction
The bankrupt gene editing biotech Sangamo is set to sell chunks of its business to PTC Therapeutics and Eli Lilly for up to $264 million following an auction procedure.